ProFarma

Executive Summary

ProFarma is a European contract laboratory and service provider specializing in quality control and batch release testing for the pharmaceutical industry, with a strong focus on biosimilars. Founded in 1991 and based in Warsaw, Poland, the company holds a Manufacturing Importation Authorization (MIA) license and GMP certification, enabling it to offer critical services for EU market access. Its expertise spans analytical development, stability testing, and Qualified Person (QP) certification for chemical compounds, biosimilars, and advanced therapies. As the biosimilar market in Europe expands, driven by patent expiries and cost-containment pressures, ProFarma is well-positioned to benefit from increased outsourcing of quality control and regulatory support. The company's established track record and regulatory credentials provide a competitive edge in the fragmented European CRO landscape. While growth is likely steady, the lack of disclosed financials and limited public visibility constrain visibility. Overall, ProFarma represents a niche, lower-risk opportunity tied to the growing demand for specialized pharmaceutical testing services.

Upcoming Catalysts (preview)

• Q3 2026Expansion of MIA License to Cell and Gene Therapies75% success
• Q4 2026Strategic Partnership with a Top-10 Biosimilar Developer60% success
• TBDNew Laboratory Facility in Western Europe70% success